靶向STUB1-组织因子轴可纠正尿毒症高血栓表型而不增加出血风险
该研究在吲哚类溶质特异性动物模型中发现,吲哚类溶质通过AHR和TF依赖的方式介导CKD各阶段的高血栓表型,AHR经STUB1调控TF。在尿毒症环境中,STUB1作为泛素连接酶与TF动态互作并使其泛素化降解;人类尿毒症血管中STUB1与TF表达呈负相关且STUB1-TF相互作用减少。遗传或药物调控血管平滑肌细胞STUB1可抑制流动环路中的血栓形成,逆转尿毒症高血栓表型而不延长出血时间,与肝素形成对比。
要点
- 吲哚类溶质经AHR和TF依赖途径介导CKD各阶段高血栓表型
- STUB1作为泛素连接酶在尿毒症环境中泛素化降解TF
- 调控STUB1可抑制血栓且不延长出血时间,与肝素不同
核心结论
- 研究细化了血栓轴,即STUB1是吲哚类溶质-AHR-TF轴的中介,并建立了在不改变止血平衡的前提下减轻尿毒症高血栓表型的手段。
研究设计与样本
- 研究采用吲哚类溶质特异性动物模型,聚焦溶质-蛋白相互作用。
- 在人类尿毒症血管中验证STUB1与TF表达关系及STUB1-TF相互作用。
- 在血管平滑肌细胞中进行STUB1的遗传或药物调控,并在流动环路中评估血栓形成。
主要发现
- 吲哚类溶质以AHR和TF依赖的方式介导CKD各阶段的高血栓表型。
- AHR通过STUB1调控TF,STUB1作为泛素连接酶在尿毒症环境中与TF动态互作并使其泛素化降解。
- 人类尿毒症血管中STUB1与TF表达呈负相关,且STUB1-TF相互作用减少。
- 血管平滑肌细胞中遗传或药物调控STUB1可抑制流动环路中的血栓形成。
- STUB1干预逆转尿毒症高血栓表型而不延长出血时间,与肝素相反。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic kidney disease (CKD/uremia) remains vexing because it increases the risk of atherothrombosis and is also associated with bleeding complications on standard antithrombotic/antiplatelet therapies. Although the associations of indolic uremic solutes and vascular wall proteins [such as tissue factor (TF) and aryl hydrocarbon receptor (AHR)] are being defined, the specific mechanisms that drive the thrombotic and bleeding risks are not fully understood. We now present an indolic solute-specific animal model, which focuses on solute-protein interactions and shows that indolic solutes mediate the hyperthrombotic phenotype across all CKD stages in an AHR- and TF-dependent manner. We further demonstrate that AHR regulates TF through STIP1 homology and U-box-containing protein 1 (STUB1). As a ubiquitin ligase, STUB1 dynamically interacts with and degrades TF through ubiquitination in the uremic milieu. TF regulation by STUB1 is supported in humans by an inverse relationship of STUB1 and TF expression and reduced STUB1-TF interaction in uremic vessels. Genetic or pharmacological manipulation of STUB1 in vascular smooth muscle cells inhibited thrombosis in flow loops. STUB1 perturbations reverted the uremic hyperthrombotic phenotype without prolonging the bleeding time, in contrast to heparin, the standard-of-care antithrombotic in CKD patients. Our work refines the thrombosis axis (STUB1 is a mediator of indolic solute-AHR-TF axis) and expands the understanding of the interconnected relationships driving the fragile thrombotic state in CKD. It also establishes a means of minimizing the uremic hyperthrombotic phenotype without altering the hemostatic balance, a long-sought-after combination in CKD patients.
引用
- Shashar M, Belghasem ME, Matsuura S, et al. Targeting STUB1-tissue factor axis normalizes hyperthrombotic uremic phenotype without increasing bleeding risk. Sci Transl Med. 2017. PMID: 29167396. doi:10.1126/scitranslmed.aam8475
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。